Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

Benzinga · 5d ago
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $28 to $25.